On February 11, 2021, Q’Apel Medical, an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, announced that it has raised $22 million in Series C funding. The round included River Cities Capital, Soleus Capital, and incumbent investor Research Corporation Technologies (RCT). Wilson Sonsini Goodrich & Rosati advised Q’Apel Medical on the transaction.

Q’Apel Medical products are being utilized in over 130 hospital systems nationwide. In 2021, Q’Apel plans to significantly increase its manufacturing capacity, add head count, and expand its product portfolio. At the same time, the company is in the process of acquiring CE certification, which will allow Q’Apel to expand into Europe later this year.

The Wilson Sonsini team that advised Q’Apel Medical on the financing includes Martin Waters, Daniel Canavan, and Meg Burton.

For more information, please see Q’Apel Medical’s press release.